Sphingosine-1-Phosphate Receptor 2 Promotes Renal Microvascular Constriction and Kidney Injury Following Renal Ischemia-Reperfusion in Rats. [PDF]
Guan Z+5 more
europepmc +1 more source
1833 QUINACRINE INHIBITS ARACHIDONIC-ACID INDUCED PULMONAR VASOCONSTRICTION [PDF]
Jav R Shavevitz+2 more
openalex +1 more source
Summary Chronic stress, characterized by increased long‐term exposure to the glucocorticoid hormone cortisol, is increasingly linked to obesity development. Still, various knowledge gaps persist, including on underlying pathophysiological mechanisms. The aim of the current review is to provide the latest insights on the connection between stress and ...
Robin Lengton+4 more
wiley +1 more source
Postpartum administration of eplerenone to mitigate vascular dysfunction in mice following a preeclampsia-like pregnancy. [PDF]
Binder NK+7 more
europepmc +1 more source
ROLE OF THE AUTONOMIC NERVOUS SYSTEM IN MEDIATING HYPOXIC PULMONARY VASOCONSTRICTION IN CONSCIOUS DOGS [PDF]
J. R. Michael+2 more
openalex +1 more source
Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator Reversing Hypoxic Pulmonary Vasoconstriction
Claes Frostell+4 more
semanticscholar +1 more source
Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases
HDACs play an important role in the occurrence and development of cardiovascular diseases, such as myocardial hypertrophy, hypertension, and atherosclerosis. HDAC inhibitors have broad prospects for the treatment of CVD, and different HDAC subtypes can act through different mechanisms.
Li‐Ying Zhang+4 more
wiley +1 more source
Response to Dr. Nicholas A. Flavahan's and Dr. Ali H. Eid's letters regarding our recent publication in Cell Genomics. [PDF]
Tervi A, Ramste M, Ollila HM.
europepmc +1 more source
DEPRESSION OF HYPOXIC PULMONARY VASOCONSTRICTION BY SODIUM NITROPRUSSIDE AND NITROGLYCERINE
Marcelo Silveira D'Oliveira+4 more
openalex +1 more source
Abstract Aims Chronic kidney disease (CKD) is a prevalent and serious complication of type 2 diabetes (T2D). This study aims to evaluate kidney outcomes in a real‐world cohort of patients with T2D and CKD who received SGLT2 inhibitors (SGLT2i) or other glucose‐lowering medications (GLM).
Gian Paolo Fadini+87 more
wiley +1 more source